BDX · NYSE · CIK 0000010795
Becton, Dickinson and Company
No equity stake in another company appears in Becton, Dickinson and Company's filings. That is the sourced answer, not a hole in the research.
Becton, Dickinson and Company - Profile
- Sector
- Health CareGICS
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
- Listed on
- NYSE
- Employees
- 72,000stated 2025
- Incorporated in
- New Jersey
- Financial year ends
- 30 September
Source
Address, industry classification, listing and incorporation come from Becton, Dickinson and Company's own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The website comes from Wikidata. The headcount is the figure the Wikipedia article states for 2025, not a figure this site has verified against a filing. The description is the opening paragraph of its Wikipedia article, used under CC BY-SA 4.0.
Share price
BDX
Description
Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas. BD is ranked #211 in the 2024 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2023.
Who owns Becton, Dickinson and Company.
sized by
modelled, reported or pending
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 1,447 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
1,447 managers reported a position, together holding 262.3m shares, or 95.2% of the company. The 40 largest are listed. Percentages are of the 275.5m shares outstanding at 31 Mar 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Waters/Biosciences separation: CLOSED, no retained BD equity stake. On 9 February 2026 BD completed the spin-off of its former Biosciences and Diagnostic Solutions business (formerly the Life Sciences segment) to BD SHAREHOLDERS, combined with Waters Corporation in a Reverse Morris Trust transaction. BD's shareholders (not BD the corporate entity) received Waters common stock representing 39.2 percent of the combined company on a fully diluted basis. BD itself received a $4 billion cash distribution from the spin-off entity, funded by $4 billion of debt incurred by that entity, not equity. BD therefore holds no equity stake in Waters or the combined company post-close; this is a sourced finding, not an omission. Source: Q3 FY2026 10-Q (period ended 30 June 2026, filed 6 August 2026), Note 2, Divestiture. BD has an October fiscal year end; the FY2025 10-K (filed 25 November 2025, period ended 30 September 2025) still described this as a 'Proposed Combination', consistent with the deal closing after that filing.
- No other equity holdings found. Searched the FY2025 10-K and the Q3 FY2026 10-Q for 'equity method', 'unconsolidated', 'joint venture', 'equity investment(s)', 'non-marketable', 'noncontrolling interest', 'affiliate', and 'investment in'. Neither filing discloses a named equity-method investee, minority stake, or a combined balance-sheet line comparable to Boston Scientific's 'Equity method investments' or 'Measurement alternative investments'. The only hit was a single generic reference in the FY2025 10-K to '(losses) gains recognized relating to certain equity investments' inside Other (income) expense, net, with no name, no balance, and no share count. Holdings is therefore an empty array as a sourced finding, not a gap.
- Capital Group checked, all three entities, none hold BDX. Per the brief's instruction to check all three Capital Group filers separately: Capital World Investors (CIK 0001422849), Capital International Investors (CIK 0001562230), and Capital Research Global Investors (CIK 0001422848) each filed a Q2 2026 13F-HR, and none contains a row for CUSIP 075887109 (Becton Dickinson) in its information table. No Capital Group row appears in the register as a result. Dodge & Cox (CIK 0000200217) was also checked and likewise has no BDX position in its Q2 2026 13F-HR.
- Vanguard case: 13F-NT (successors summed). Vanguard Group Inc (CIK 0000102909) filed Form 13F-NT for Q2 2026 (accession 0000102909-26-002714), meaning it reported no holdings itself. Its BDX position is carried by two successor filers, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC, which are summed into one 'Vanguard Group' row per the brief's rule for the 13F-NT case.
- Starboard Value: no live Schedule 13D found. Starboard Value has been reported in the press as an activist pushing BD to separate its former Life Sciences/Biosciences unit, a campaign that appears consistent with the Waters transaction that ultimately closed. EDGAR's full filing history for BD (CIK 0000010795) contains no SC 13D or SC 13D/A of any kind, past or present; the only Schedule 13-series filings on file are SC 13G / SC 13G/A (passive, from index and institutional holders such as Vanguard, T. Rowe Price, First Eagle). No Starboard 13D exists on EDGAR for this issuer as of 17 August 2026, so no Starboard row is included in the register.
- T. Rowe Price Associates, Inc. (CIK 0000080255) reports its Q2 2026 13F-HR value field in thousands of dollars rather than whole dollars for its BDX lines; rescaled per the method_note on that register row.
- Register rows First Eagle Investment Management and Invesco Ltd. are not on the brief's pre-verified manager CIK list; they were added because the Q1 2026 (31-Mar-2026) register snapshot at data/registers/BDX.json showed both as larger holders than several pre-verified names (First Eagle 11.9m sh, Invesco 10.2m sh at that date), so both were individually verified against their own Q2 2026 13F-HR filings to keep the top-12 register accurate rather than relying on the pre-verified list alone.
- Percentages for the 12 institutional rows use 272,386,800 common shares outstanding as of 30 June 2026 (Q3 FY2026 10-Q cover page). The two proxy-sourced insider rows use the proxy's own record-date denominator of 284,908,096 shares as of 8 December 2025.
- Market capitalisation ($49,598,912,412) is computed as 272,386,800 shares outstanding x $182.09 close on 17 August 2026 (stockanalysis.com), which is consistent with stockanalysis.com's own reported market cap of approximately $49.60 billion for that date.
- Self-gate check: institutional rows (12) sum to 136,905,849 shares. The Polen row counts at full value (527,589, a member row rolling into the group aggregate). The group-aggregate row counts reduced by the member it contains: 1,134,105 minus 527,589 = 606,516. Total: 136,905,849 + 527,589 + 606,516 = 138,039,954 shares against 272,386,800 outstanding, or 50.68 percent, across 14 register rows. Within the expected 15 to 55 percent range.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- MFS's Q2 2026 13F-HR for Becton Dickinson contains one line that cannot be reconciled: 1,152,058 shares against 1,295,470,097 dollars, about 1,124 dollars per share, where its other eight lines and every other filer imply about 151. Either that line's value is overstated or its share count is understated. The share total is used as filed and the value is left null. Resolving it would need MFS's own amendment or a 13G/A, neither of which was located.
- The dollar value split, if any, of BD's $4 billion cash distribution from the Waters spin-off entity versus other consideration; the Q3 FY2026 10-Q states the distribution was funded entirely by debt incurred by the spin-off entity and does not suggest BD retained any equity, but no balance-sheet line naming a residual Waters interest was found to confirm a literal zero beyond the absence of any such line.
- Holders ranked below Schwab IM on institutional-ownership aggregators (for example Clearbridge Investments, American Century, Goldman Sachs, Nordea Investment Management, Northern Trust, Morgan Stanley, JPMorgan, Bank of America, Wells Fargo, FMR/Fidelity) were checked against their own Q2 2026 13F-HR filings for scale comparison but fell below the 12 largest positions found and are not included as separate register rows: JPMorgan 2,835,692 sh, Morgan Stanley 3,319,590 sh, Bank of America 3,138,786 sh, Northern Trust 2,625,220 sh, Wells Fargo 1,210,775 sh, FMR/Fidelity 459,929 sh, all as of 30 June 2026, all smaller than the 12 rows included.
- No independent full-text EDGAR search for a fresh SC 13D or SC 13G on BDX outside the issuer's own filing history was run; the register relies on CIK 0000010795's own EDGAR filing list, which is the authoritative venue for filings naming BD as the subject company.
- No named individual constituents inside BD's generic 'certain equity investments' language (Other (income) expense, net) in the FY2025 10-K were identified; the filing does not break this out by investee or give a balance.